A phase II study of tepotinib in patients with advanced solid cancers harboring MET exon 14 skipping mutations or amplification (KCSG AL19-17).
Kang EJ, Yang Y, Lee S, Kim YJ, Lim SM, Ahn MJ, Choi YJ, Lee Y, Kim TM, Kim I, Ahn HK, Jeung HC, Lee SI, Oh SY, Bae WK, Ryu H, Park KH, Lee KH.
Kang EJ, et al. Among authors: lee si, lee y, lee kh, lee s.
ESMO Open. 2024 Sep;9(9):103668. doi: 10.1016/j.esmoop.2024.103668. Epub 2024 Aug 29.
ESMO Open. 2024.
PMID: 39214049
Free PMC article.
Clinical Trial.